Scailyte
Basel
About Scailyte
Scailyte has established a data-driven biomarker discovery platform that leverages unique expertise in single-cell data analysis and artificial intelligence. We are utilizing this platform to discover a new class of biomarkers, which are defined by the molecular profiles of disease-associated cells. This phenotypic approach to biomarker discovery is radically new and directly related to the biology of a disease, which maximizes the success rate for discovering sensitive and robust biomarkers.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $15.6M
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2023)
- Website: scailyte.com
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Health Care, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/scailyte-128443 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.